Focus on HIV Care

Back to articles

Longer term efficacy data released for maraviroc

KEY POINT

 

Results from two 48-week, double-blind, placebo-controlled Phase III trials showed that patients with previously treated R5 HIV-1 infection who were randomized to maraviroc (Selzentry—Pfizer) had significantly greater reductions of HIV-1 RNA levels and greater increases in CD4 cell counts compared with placebo.

SOURCES

Gulick RM et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429–41.

Fatkenheuer G et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359:1442–55.

Dolin R. A new class of anti-HIV therapy and new challenges [editorial]. N Engl J Med. 2008;359:1509–11.